NEW YORK – Myriad Genetics on Tuesday announced five research collaborations to study the use of the company's Precise MRD assay in breast cancer minimal residual disease (MRD) monitoring.
A study led by the MD Anderson Cancer Center aims to determine whether circulating tumor DNA (ctDNA) levels can predict a patient's response to Merck's Keytruda (pembrolizumab) and hormonal therapy in individuals with hormone receptor-positive inflammatory breast cancer who did not achieve pathological complete response at the time of surgery.
Another study done with the University of Rochester Medical Center will evaluate whether ctDNA levels correlate with nodal involvement in patients with newly diagnosed HR-positive breast cancer. If so, the study will also investigate how that can be used to support clinical decision-making.
A third project, done in collaboration with the Cleveland Clinic, will study the association between ctDNA levels and both neoadjuvant and adjuvant therapy in approximately 650 patients with any subtype of newly diagnosed breast cancer.
A multicenter, prospective study done in collaboration with the National Cancer Center Hospital East in Japan will evaluate the maintenance of complete response with trastuzumab deruxtecan (AstraZeneca and Daiichi Sankyo's Enhertu) in HER2-positive advanced or metastatic breast cancer patients, as well as whether ctDNA can be used to guide therapy.
Finally, Myriad will assess ctDNA levels in high-risk patients at diagnosis, during neoadjuvant treatment, and following surgery in community oncology settings with Aptitude Health.
Separately, the Salt Lake City-based molecular diagnostics company also disclosed Q3 revenue estimates in advance of its quarterly earnings call. The company expects to report between $210 million and $212 million in revenue despite having divested Myriad's European EndoPredict business in August.
The firm also reaffirmed in a US Securities and Exchange Commission filing its previous full-year 2024 financial guidance of revenues between $835 million and $845 million.